CVS Health (CVS)
(Delayed Data from NYSE)
$59.32 USD
-0.71 (-1.18%)
Updated Aug 2, 2024 04:00 PM ET
Pre-Market: $58.20 -1.12 (-1.89%) 8:28 AM ET
4-Sell of 5 4
A Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$59.32 USD
-0.71 (-1.18%)
Updated Aug 2, 2024 04:00 PM ET
Pre-Market: $58.20 -1.12 (-1.89%) 8:28 AM ET
4-Sell of 5 4
A Value A Growth B Momentum A VGM
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
Here is What to Know Beyond Why CVS Health Corporation (CVS) is a Trending Stock
by Zacks Equity Research
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CVS Health's (CVS) Cordavis to Focus on Biosimilar Products
by Zacks Equity Research
CVS Health's (CVS) wholly owned subsidiary, Cordavis, is set to bring high-quality biosimilar products to the market.
The Zacks Analyst Blog Highlights Merck, Philip Morris, Qualcomm, CVS Health and Chubb
by Zacks Equity Research
Merck, Philip Morris, Qualcomm, CVS Health and Chubb are included in this Analyst Blog.
Top Stock Reports for Merck, Philip Morris & QUALCOMM
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Philip Morris International Inc. (PM) and QUALCOMM Incorporated (QCOM).
Is Trending Stock CVS Health Corporation (CVS) a Buy Now?
by Zacks Equity Research
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health's (CVS) continued growth across the insured and self-insured medical, pharmacy, dental and behavioral health products and services.
Walgreens (WBA) and VillageMD Expand Partnership in Chicago
by Zacks Equity Research
Walgreens (WBA) and VillageMD's coordinated primary care and pharmacy services are now available in Chicago.
CVS Health (CVS) Q2 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Pharmacy drug mix, growth in specialty pharmacy, brand inflation and the acquisitions of Oak Street Health and Signify Health drive CVS Health's (CVS) Q2 revenues.
Private Sector Jobs Come in Higher Than Expected
by Zacks Equity Research
Private Sector Jobs Come in Higher Than Expected.
ADP Jobs +324K Still Higher than Expected; CVS, KHC, HUM Report
by Mark Vickery
ADP Chief Economist Nela Richardson said, "The economy is doing better than expected... we continue to see a slowdown in pay growth without broad-based job loss."
CVS Health (CVS) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for CVS Health (CVS) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
CVS Health (CVS) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
CVS Health (CVS) delivered earnings and revenue surprises of 4.25% and 2.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
CVS Health (CVS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
We expect brand price inflation, new product launch, higher utilization and new PBM clients to have contributed to second-quarter growth for CVS Health (CVS).
Earnings Preview: CVS Health (CVS) Q2 Earnings Expected to Decline
by Zacks Equity Research
CVS Health (CVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVS Health (CVS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $75.95 in the latest trading session, marking a +1.2% move from the prior day.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Zacks Industry Outlook Highlights CVS Health, Herbalife, Rite Aid and Amazon
by Zacks Equity Research
CVS Health, Herbalife, Rite Aid and Amazon have been highlighted in this Industry Outlook article.
3 Retail Pharmacy and Drugstore Stocks to Watch Amid Industry Headwinds
by Urmimala Biswas
The Zacks Retail Pharmacy and Drugstore industry players like CVS, HLF and RAD are likely to gain despite reimbursement challenges hurting the overall industry health.
CVS Health (CVS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $72.31 in the latest trading session, marking a +1.6% move from the prior day.
Is Most-Watched Stock CVS Health Corporation (CVS) Worth Betting on Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
CVS Health (CVS) Launches Caremark Cost Saver With a New Pact
by Zacks Equity Research
CVS Health (CVS) is able to dynamically shop for the lowest price on its clients' behalf with the help of Caremark Cost Saver solution.
Is It Worth Investing in CVS Health (CVS) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in CVS Health (CVS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $70.46, marking a -1.14% move from the previous day.
CVS Health (CVS) Stock Moves -0.07%: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $69.54, marking a -0.07% move from the previous day.
CVS Health (CVS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $68.14 in the latest trading session, marking a -0.79% move from the prior day.